Skip to main content
Abrdn PLC logo

Abrdn PLC — Investor Relations & Filings

Ticker · ABDN ISIN · GB00BF8Q6K64 LEI · 0TMBS544NMO7GLCE7H90 IL Financial and insurance activities
Open in API
Filings indexed 4,550 across all filing types
Latest filing 2021-12-17 Director's Dealing
Country GB United Kingdom
Listing IL ABDN

About Abrdn PLC

https://www.abrdn.com/en-gb

Abrdn PLC is a global investment company and asset manager formed from the 2017 merger of Standard Life and Aberdeen Asset Management. The firm offers a range of investment solutions, funds, and investment trusts. It serves a diverse client base that includes individual customers, financial advisers, wealth managers, and institutional investors. The company focuses on providing expertise and tools to help clients manage and grow their wealth, enabling them to prepare for their financial future.

Recent filings

Filing Released Lang Actions
Form 8.3 - Clinigen Group plc
Director's Dealing Classification · 95% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code (the "Code")'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to insider or significant shareholder dealings during a takeover scenario. While it involves dealings (DIRS) and regulatory reporting (RNS), the specific nature of a Form 8.3 disclosure regarding interests in securities during a takeover bid points most closely to a specialized regulatory filing concerning insider/director transactions or major shareholdings, but given the options, it is a specific regulatory disclosure related to a takeover. Since there is no specific code for 'Takeover Disclosure Form 8.3', we must evaluate the closest fit. It details dealings by a director/insider (abrdn plc) concerning an offeror/offeree (Clinigen Group plc). This is a form of insider dealing disclosure, but it is mandated by the Takeover Code, not standard insider trading rules (which would be DIRS). Given the context of regulatory reporting and the specific nature of the form, it is best classified as a general Regulatory Filing (RNS) as it is a mandatory disclosure to the Regulatory Information Service (RNS) concerning a specific event (takeover activity), which is the fallback for specific regulatory forms not explicitly listed. However, since it details personal share transactions by an entity involved in a takeover, it is highly related to Director's Dealing (DIRS). Since DIRS is defined as 'Report of personal share transactions by company directors and executives (insider trades)', and this is a mandatory disclosure of position and dealing by a major shareholder/insider during a takeover, DIRS is a strong candidate. Given the document is a mandatory disclosure to the RNS system, RNS is the safest general regulatory classification if DIRS is interpreted strictly as routine insider trading outside of a takeover context. However, Form 8.3 is fundamentally about disclosing interests/dealings. Let's re-examine the definitions. DIRS is for 'Director's Dealing'. This is a disclosure by 'abrdn plc' regarding 'Clinigen Group plc'. It is a dealing disclosure. I will classify it as DIRS as it reports dealings/positions of an interested party, which aligns with the spirit of DIRS, even if mandated by takeover rules. If DIRS is too narrow, RNS is the fallback. Given the detailed nature of the dealing tables, DIRS seems more specific than RNS.
2021-12-17 English
Form 8.3 - Vivo Energy plc
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is used for 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' concerning an offeror/offeree (Vivo Energy PLC). This type of mandatory disclosure related to takeover activity and insider/significant shareholder dealings is a specific regulatory filing. While it relates to director/insider dealings (DIRS), Form 8.3 is a specific Takeover Code filing related to an ongoing M&A situation, which is best categorized under the general regulatory filing umbrella, or potentially DIRS if the context was purely about insider trading outside of a formal offer. However, given the explicit reference to the Takeover Code and the structure of the filing, it is a specific regulatory disclosure. Since there is no specific code for 'Takeover Code Disclosure Form 8.3', and it involves dealing disclosures, it falls under the general 'Regulatory Filings' (RNS) category as a mandatory public disclosure, or potentially DIRS if we prioritize the content over the specific form type. Given the context of the Takeover Code, RNS is the most appropriate general regulatory bucket for mandatory disclosures not covered by other specific codes like 10-K or ER. However, since the content is fundamentally about director/insider dealing in the context of an offer, and DIRS covers 'Report of personal share transactions by company directors and executives (insider trades)', this is a strong candidate. Let's re-evaluate the definitions. DIRS is for general insider trades. This is a specific disclosure under the Takeover Code (Rule 8.3) during an offer period. RNS is the fallback for miscellaneous regulatory filings. Since this is a highly specific regulatory filing mandated by the Takeover Panel, RNS is the most accurate fit among the provided options for a non-standard, mandatory disclosure.
2021-12-17 English
Directorate Change
Board/Management Information Classification · 100% confidence The document is an official announcement from 'abrdn PLC' filed via 'RNS Number : 9581V' on '17 December 2021'. The subject is 'Directorate change', specifically announcing the appointment of Catherine Bradley as a Non-Executive Director. This content directly relates to changes in the company's board of directors or senior management. This matches the definition for Board/Management Information (MANG). Although it is filed via RNS, the specific content is not general regulatory news but a specific management update.
2021-12-17 English
Form 8.3 - Clinigen Group plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is used for 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' in the context of an offer (here, involving Clinigen Group plc). This type of disclosure relates to insider/major shareholder dealings during a takeover scenario. While it involves dealings, the specific regulatory form (Form 8.3) is a specialized disclosure related to takeover activity, which is not explicitly covered by 'DIRS' (Director's Dealing, which usually refers to Form 3/4/5 equivalents or general insider trading reports). However, the core activity described is the disclosure of interests and dealings by a person involved in a takeover. Given the options, 'Director's Dealing' (DIRS) is the closest fit for reporting personal share transactions/interests by an involved party, although 'Major Shareholding Notification' (MRQ) or 'Regulatory Filings' (RNS) are also possibilities. Since this is a mandatory disclosure under the Takeover Code regarding interests/dealings in securities during an offer, and it is not a standard 10-K, ER, or IR, it falls under the category of insider/significant transaction reporting. 'DIRS' covers personal share transactions by directors/executives. Since this is a major shareholder/interested party disclosure during a takeover, it is a form of insider transaction reporting. If a more specific 'Takeover Disclosure' code existed, it would be used. Lacking that, 'DIRS' is the most appropriate category for reporting personal security interests/dealings by an involved party, or 'RNS' as a general regulatory filing. Given the specific nature of the disclosure (Rule 8.3), it is a highly specific regulatory filing. I will classify it as 'RNS' (Regulatory Filings) as it is a mandatory disclosure to the RNS service under the Takeover Code, which doesn't fit the other specific financial report types, and is more specific than general DIRS which often implies director-only trades.
2021-12-15 English
Form 8.3 - Clinigen Group plc
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is used for 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' concerning an offeror/offeree (Clinigen Group plc). This type of disclosure relates to insider dealings or significant ownership changes during a takeover scenario. While it involves director/insider activity (similar to DIRS), the specific context of the Takeover Code disclosure (Form 8.3) is not explicitly covered by the provided definitions (AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, RNS, DEF 14A, RPA, SHA, POS). However, Form 8.3 is a mandatory regulatory filing related to M&A activity (Takeover Code) and insider transactions. Since 'DIRS' (Director's Dealing) is for general insider trades, and 'TAR' (M&A Activity) covers merger proposals, the most appropriate general regulatory category for a specific, mandatory disclosure related to a takeover situation, which doesn't fit the other specific codes, is the general regulatory filing category. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback category) is the best fit for a specific, non-standard regulatory form like Form 8.3 that doesn't map directly to the other specific categories like DIRS (which usually implies routine insider reporting outside of a formal takeover context) or TAR (which is broader M&A activity). The document is clearly a regulatory filing disseminated via RNS.
2021-12-14 English
Form 8.3 - Clinigen Group plc
Director's Dealing Classification · 98% confidence The document is explicitly titled 'FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' and references 'Rule 8.3 of the Takeover Code'. This form is used to disclose insider dealings or significant ownership changes related to a takeover offer (here involving Clinigen Group plc). This type of disclosure, which reports personal share transactions by executives or major shareholders related to a specific corporate action (like a takeover), aligns most closely with the 'Director's Dealing' category (DIRS), although it is specifically a Takeover Code disclosure. Since DIRS covers personal share transactions by directors and executives, and this document details the holdings and dealings of abrdn plc (a major shareholder/controller) in relation to an offer, DIRS is the most appropriate fit among the provided codes, as it captures insider/significant holder transaction reporting. It is not a general regulatory filing (RNS) because it is a highly specific form (Form 8.3).
2021-12-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.